← Back to Clinical Trials
Recruiting NCT05207098

NCT05207098 A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05207098
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Head and Neck Cancer
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2021-12-22
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 89 Years
Study Type OBSERVATIONAL
Interventions
Neurocognitive TestsQuestionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2021-12-22 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The researchers are doing this study to collect more information about if, and how, neurocognitive function may be affected in people being treated with radiation therapy for head and neck cancer. Part of this study is to see if patients diagnosed with head and neck cancer who are undergoing radiation therapy are able to complete neurocognitive testing and questionnaires at 3 times over a period of 1 year.

Eligibility Criteria

Inclusion Criteria: * Pathologically proven diagnosis of a head and neck cancer, specifically these subtypes: nasopharynx, maxillary sinus, tonsil, base of the tongue, oral cavity, or larynx/hypopharynx, oropharynx, cancer of unknown primary, or salivary gland. * Ages ≥ 18 and \<89 at time of diagnosis. * Recently diagnosed with their initial head and neck cancer and able to be consented prior to OR within first week of starting standard of care radiation therapy. * Baseline simulation whole-brain MRI or CT available as part of standard of care. * Patients diagnosed with cancer, no distant metastases. * Karnofsky Performance Status of \>= 70 or comparable ECOG performance at enrollment. * As per self-report, if currently taking psychoactive medications (excluding gabapentin and including but not limited to antidepressants, and anxiolytics) on a daily basis, dose must have been stable for at least two months prior to enrollment. * English fluent as per self-reported fluency of "well' or "very well", and having a reasonable comprehension of the study conversation in the opinion of the research staff).\*\* \*\* Language verification: Prior to enrollment, all patients will be asked the following two questions by the CRC to verify English fluency necessary for participation in the study: 1. How well do you speak English? Must respond "Well" or "Very well" when given the choices of: Very well, Well, Not well, Not at all, Don't know, or Refused. 2. What is your preferred language for healthcare? Must respond English. Exclusion Criteria: * Patients with multiple primary head and neck cancers, carcinoma of unknown primary, or recurrence. * Patients who previously received radiation therapy to the head and neck region as treatment for any prior cancer for any other non-cancerous condition. * Patients who had chemotherapy within two years prior to their recent diagnosis of head and neck cancer, such as patients who received chemotherapy as treatment for any other type of cancer or received neoadjuvant chemotherapy prior to surgery to treat their recent head and neck diagnosis. Patients who receive induction chemotherapy just prior to the start of their radiation therapy or receive concurrent chemotherapy to treat their recent head and neck diagnosis are allowed * At the discretion of the clinician, patients who are unable to comfortably speak due to symptoms of their cancer or treatment, such as surgery. * Pre-existing diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.). * As per medical record or self-report, history of stroke or head injury requiring medical care, confirmed structural lesion on neuroimaging, and persistent cognitive difficulties impacting work or daily life or required cognitive rehabilitation. * Pre-existing diagnosis of a Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder. * Pre-existing visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids)

Contact & Investigator

Central Contact

Jonine Bernstein, PhD

✉ bernstej@mskcc.org

📞 646-888-8241

Principal Investigator

Jonine Bernstein, PhD

PRINCIPAL INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions

Who can join the NCT05207098 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05207098 currently recruiting?

Yes, NCT05207098 is actively recruiting participants. Contact the research team at bernstej@mskcc.org for enrollment information.

Where is the NCT05207098 trial being conducted?

This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.

Who is sponsoring the NCT05207098 clinical trial?

NCT05207098 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Jonine Bernstein, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology